JonesResearch lowered the firm’s price target on Femasys (FEMY) to $6 from $10 and keeps a Buy rating on the shares. The company reported Q1 earnings with no major updates to catalysts or its cash runway, the analyst tells investors in a research note. The firm remains positive on Femasys, but cut its price target to reflect the delayed launch of FemaSeed and an increase in share count from potential financing in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys’s Growth Potential Highlighted by U.S. Revenue Surge and Strategic Partnerships
- Femasys Positioned for Growth with Innovative Products and Strategic Partnerships
- Femasys Positioned for Growth in 2025 with Strategic Partnerships and Regulatory Progress
- Femasys reports FY24 EPS (85c), consensus (81c)
- FEMY Upcoming Earnings Report: What to Expect?